Travere Therapeutics logo

Travere Therapeutics Share Price Today

(NASDAQ: TVTX)

Travere Therapeutics share price is $19.42 & ₹1,688.94 as on 6 Mar 2025, 2.30 'hrs' IST

$19.42

-0.28

(-1.42%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Travere Therapeutics share price in Dollar and Rupees. Guide to invest in Travere Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Travere Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Travere Therapeutics share price movements

  • Today's Low: $18.91
    Today's High: $19.73

    Day's Volatility :4.16%

  • 52 Weeks Low: $5.12
    52 Weeks High: $25.29

    52 Weeks Volatility :79.75%

Travere Therapeutics (TVTX) Returns

PeriodTravere Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
1.49%
2.1%
0.0%
6 Months
98.39%
-4.1%
0.0%
1 Year
128.8%
2.2%
0.0%
3 Years
-26.13%
11.8%
-11.6%

Travere Therapeutics (TVTX) Key Statistics

in dollars & INR

Previous Close
$19.7
Open
$19.35
Today's High
$19.73
Today's Low
$18.91
Market Capitalization
$1.8B
Today's Volume
$593.7K
52 Week High
$25.29
52 Week Low
$5.12
Revenue TTM
$233.2M
EBITDA
$-212.6M
Earnings Per Share (EPS)
$-4.07
Profit Margin
-137.9%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-246.75%

How to invest in Travere Therapeutics Stock (TVTX) from India?

It is very easy for Indian residents to invest directly in Travere Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Travere Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Travere Therapeutics or TVTX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Travere Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Travere Therapeutics shares which would translate to 0.045 fractional shares of Travere Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Travere Therapeutics, in just a few clicks!

Returns in Travere Therapeutics (TVTX) for Indian investors in Rupees

The Travere Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Travere Therapeutics investment value today

Current value as on today

₹2,30,514

Returns

₹1,30,514

(+130.51%)

Returns from Travere Therapeutics Stock

₹1,25,552 (+125.55%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Travere Therapeutics (TVTX)

111%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Travere Therapeutics Stock from India on INDmoney has increased by 111% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Travere Therapeutics

  • BlackRock Inc

    9.04%

  • Armistice Capital, LLC

    8.29%

  • Vanguard Group Inc

    7.60%

  • Rock Springs Capital Management LP

    5.60%

  • Macquarie Group Ltd

    4.80%

  • HHG PLC

    4.57%

Analyst Recommendation on Travere Therapeutics

Buy

    72%Buy

    27%Hold

    0%Sell

Based on 22 Wall street analysts offering stock ratings for Travere Therapeutics(by analysts ranked 0 to 5 stars)

Based on 22 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
17
Hold
6
6
5
Sell
0
0
0

Analyst Forecast on Travere Therapeutics Stock (TVTX)

What analysts predicted

Upside of 74.05%

Target:

$33.80

Current:

$19.42

Insights on Travere Therapeutics Stock (Ticker Symbol: TVTX)

  • Price Movement

    In the last 6 months, TVTX stock has moved up by 98.4%
  • Increasing Revenue

    Revenue is up for the last 4 quarters, 41.37M → 74.78M (in $), with an average increase of 17.8% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -54.81M → -60.26M (in $), with an average decrease of 10.0% per quarter
  • TVTX vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 72.8%

Travere Therapeutics Technicals Summary

Sell

Neutral

Buy

Travere Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Travere Therapeutics (TVTX) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Travere Therapeutics Inc logo
-2.57%
98.39%
128.8%
-26.13%
32.3%
Regeneron Pharmaceuticals, Inc. logo
1.3%
-41.29%
-30.51%
9.2%
42.38%
Beone Medicines Ltd logo
15.19%
34.31%
61.3%
43.16%
68.1%
Vertex Pharmaceuticals Incorporated logo
3.37%
3.77%
18.06%
106.43%
121.36%
Alnylam Pharmaceuticals, Inc. logo
-11.52%
-3.4%
62.32%
49.04%
120.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Travere Therapeutics Inc logo
NA
NA
NA
-0.33
-2.47
-0.23
NA
0.68
Regeneron Pharmaceuticals, Inc. logo
17.85
17.85
1.03
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.33
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Travere Therapeutics Inc logo
Buy
$1.8B
32.3%
NA
-137.9%
Regeneron Pharmaceuticals, Inc. logo
Buy
$74.9B
42.38%
17.85
31.07%
Beone Medicines Ltd logo
NA
$28.5B
68.1%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.1B
121.36%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.5B
120.93%
NA
-12.37%

About Travere Therapeutics

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Organization
Travere Therapeutics
Employees
385
CEO
Dr. Eric M. Dube Ph.D.
Industry
Health Technology

Management People of Travere Therapeutics

NameTitle
Dr. Eric M. Dube Ph.D.
President, CEO & Director
Mr. Christopher Cline C.F.A.
Chief Financial Officer
Ms. Elizabeth E. Reed J.D.
Senior VP, General Counsel & Corporate Secretary
Dr. William E. Rote Ph.D.
Senior VP and Head of Research & Development
Mr. Peter Heerma
Chief Commercial Officer
Ms. Sandra Calvin
SVP, Corporate Controller & Chief Accounting Officer
Ms. Nivi Nehra
Vice President of Corporate Communications & Investor Relations
Ms. Angela Giannantonio
Senior Vice President of Human Resources
Mr. Casey Logan
Chief Business Officer
Dr. Jula Inrig M.D.
Chief Medical Officer

Important FAQs about investing in TVTX Stock from India :

What is Travere Therapeutics share price today?

Travere Therapeutics share price today stands at $19.42, Open: $19.35 ; Previous Close: $19.70 ; High: $19.73 ; Low: $18.91 ; 52 Week High: $25.29 ; 52 Week Low: $5.12.

The stock opens at $19.35, after a previous close of $19.70. The stock reached a daily high of $19.73 and a low of $18.91, with a 52-week high of $25.29 and a 52-week low of $5.12.

Can Indians buy Travere Therapeutics shares?

Yes, Indians can invest in the Travere Therapeutics (TVTX) from India.

With INDmoney, you can buy Travere Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Travere Therapeutics at zero transaction cost.

How can I buy Travere Therapeutics shares from India?

It is very easy to buy Travere Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Travere Therapeutics (TVTX) be purchased?

Yes, you can buy fractional shares of Travere Therapeutics with INDmoney app.

What are the documents required to start investing in Travere Therapeutics stocks?

To start investing in Travere Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Travere Therapeutics Stock (TVTX)?

Today’s highest price of Travere Therapeutics (TVTX) is $19.73.

Today’s lowest price of Travere Therapeutics (TVTX) is $18.91.

What is today's market capitalisation of Travere Therapeutics?

Today's market capitalisation of Travere Therapeutics TVTX is 1.8B

What is the 52 Week High and Low Range of Travere Therapeutics Stock (TVTX)?

  • 52 Week High

    $25.29

  • 52 Week Low

    $5.12

What are the historical returns of Travere Therapeutics (TVTX)?

  • 1 Month Returns

    -2.57%

  • 3 Months Returns

    98.39%

  • 1 Year Returns

    128.8%

  • 5 Years Returns

    32.3%

Who is the Chief Executive Officer (CEO) of Travere Therapeutics ?

Dr. Eric M. Dube Ph.D. is the current Chief Executive Officer (CEO) of Travere Therapeutics.